Royalty Pharma (RPRX) Intangibles (2019 - 2021)

Royalty Pharma has disclosed Intangibles across 3 years of filings, most recently posting $5.7 million for Q4 2021.

• Intangibles for Q4 2021 came in at $5.7 million, down 80.22% year-over-year; the trailing twelve-month figure through Dec 2021 was $5.7 million (down 80.22% YoY), and the FY2021 annual result was $5.7 million, down 80.22% from the prior year.
• Intangibles came in at $5.7 million for Q4 2021 at Royalty Pharma, down from $11.5 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $51.7 million in Q4 2019 to a low of $5.7 million in Q4 2021.
• The 3-year median for Intangibles is $25.8 million (2020), against an average of $26.6 million.
• Across the five-year window, Intangibles sank 44.58% in 2020 and tumbled 80.22% in 2021, its largest moves.
• Royalty Pharma's Intangibles stood at $51.7 million in 2019, then tumbled by 44.58% to $28.7 million in 2020, then sank by 80.22% to $5.7 million in 2021.
• The last three Intangibles figures came in at $5.7 million (Q4 2021), $11.5 million (Q3 2021), and $17.3 million (Q2 2021), per Business Quant data.